Merck PE Ratio 2006-2018 | MRK

Current and historical PE ratio for Merck (MRK) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Merck (MRK) as of March 31, 2018 is 15.17.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.973B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $342.875B 16.39
Pfizer (PFE) United States $224.185B 13.80
Novartis AG (NVS) Switzerland $187.621B 16.09
AbbVie (ABBV) United States $149.801B 15.27
Novo Nordisk (NVO) Denmark $122.714B 20.33
Sanofi (SNY) France $105.515B 13.36
GlaxoSmithKline (GSK) United Kingdom $101.582B 13.89
Eli Lilly (LLY) United States $97.721B 19.40
AstraZeneca (AZN) United Kingdom $94.553B 9.90
Bristol-Myers Squibb (BMY) United States $92.973B 18.29